U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H14ClN3O.ClH
Molecular Weight 336.2163
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORDIAZEPOXIDE HYDROCHLORIDE

SMILES

CN=C1CN(=C(c2ccccc2)c3cc(ccc3N1)Cl)=O.Cl

InChI

InChIKey=DMLFJMQTNDSRFU-UHFFFAOYSA-N
InChI=1S/C16H14ClN3O.ClH/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15;/h2-9H,10H2,1H3,(H,18,19);1H

HIDE SMILES / InChI

Molecular Formula C16H14ClN3O
Molecular Weight 299.7554
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT00136617 | https://www.drugs.com/pro/chlordiazepoxide.html | https://clinicaltrials.gov/ct2/show/NCT03012815 | https://www.ncbi.nlm.nih.gov/pubmed/6135616 | https://www.ncbi.nlm.nih.gov/pubmed/6304314

Chlordiazepoxide (trade name Librium) is a sedative and hypnotic medication of the benzodiazepine class. Chlordiazepoxide is indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of Librium in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. Chlordiazepoxide acts on benzodiazepine allosteric sites that are part of the GABAA receptor/ion-channel complex and this results in an increased binding of the inhibitory neurotransmitter GABA to the GABAA receptor thereby producing inhibitory effects on the central nervous system and body similar to the effects of other benzodiazepines. Chlordiazepoxide act via micromolar benzodiazepine binding sites as Ca2+ channel blockers and significantly inhibit depolarization-sensitive Calcium uptake in animal nerve terminal preparations. The withdrawal of chlordiazepoxide during pregnancy and breastfeeding is recommended, as chlordiazepoxide rapidly crosses the placenta and also is excreted in breast milk. Chlordiazepoxide is a long-acting benzodiazepine drug. The half-life of Chlordiazepoxide is 5 – 30 hours but has an active benzodiazepine metabolite (desmethyldiazepam), which has a half-life of 36 – 200 hours. The necessity of discontinuing therapy because of undesirable effects has been rare. Drowsiness, ataxia and confusion have been reported in some patients — particularly the elderly and debilitated. While these effects can be avoided in almost all instances by proper dosage adjustment, they have occasionally been observed at the lower dosage ranges. In a few instances syncope has been reported.

Originator

Sources: International Journal of Neuropharmacology (1955), 5, (4), 305-10

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LIBRELEASE

Approved Use

Chlordiazepoxide HCl capsules USP are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide HCl capsules USP in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Launch Date

4.32172794E11
Primary
LIBRELEASE

Approved Use

Chlordiazepoxide HCl capsules USP are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide HCl capsules USP in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Launch Date

4.32172794E11
Primary
LIBRELEASE

Approved Use

Chlordiazepoxide HCl capsules USP are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide HCl capsules USP in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Launch Date

4.32172794E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.86 μg/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE blood
Homo sapiens
population: UNKNOWN
age: ADULT
sex: MALE
food status: UNKNOWN
1.65 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE blood
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.84 μg/mL
25 mg single, intramuscular
dose: 25 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.69 μg/mL
25 mg single, intramuscular
dose: 25 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7.16 μg × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
26.7 μg × h/mL
25 mg single, intramuscular
dose: 25 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
53.6 μg × h/mL
25 mg single, intramuscular
dose: 25 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.4 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16.5 h
25 mg single, intramuscular
dose: 25 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
40.1 h
25 mg single, intramuscular
dose: 25 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CHLORDIAZEPOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95.5%
CHLORDIAZEPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, 24-74 years
Health Status: unhealthy
Age Group: 24-74 years
Sex: M+F
Sources:
20 mg 3 times / day multiple, oral
Studied dose
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Co-administed with::
opioids
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Severe Anxiety Disorders
Age Group: adult
Sources:
Disc. AE: Sedation, Coma...
AEs leading to
discontinuation/dose reduction:
Sedation
Coma
Respiratory depression
Sources:
AEs

AEs

AESignificanceDosePopulation
Coma Disc. AE
20 mg 3 times / day multiple, oral
Studied dose
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Co-administed with::
opioids
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Severe Anxiety Disorders
Age Group: adult
Sources:
Respiratory depression Disc. AE
20 mg 3 times / day multiple, oral
Studied dose
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Co-administed with::
opioids
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Severe Anxiety Disorders
Age Group: adult
Sources:
Sedation Disc. AE
20 mg 3 times / day multiple, oral
Studied dose
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Co-administed with::
opioids
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Severe Anxiety Disorders
Age Group: adult
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Cholestatic jaundice associated with chlordiazepoxide hydrochloride (Librium) therapy. Report of a case and review of the literature.
1967 Aug
Chlordiazepoxide and hallucinations. Report of cases.
1968 Sep
Unusual effect of fenfluramine.
1969 Nov 29
Hypotensive effects of chlordiazepoxide, amobarbital and chlorpromazine on behaviorally induced elevated arterial blood pressure in the squirrel monkey.
1970 Jun
Clinical electronystagmography.
1971 Jan
Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program.
1974 Jul 26
Letter: Psychotic symptoms due to meperidine intoxication.
1974 Jun 8
Bromazepam, medazepam, chlordiazepoxide in treatment of neurotic anxiety.
1974 May
Disulfiram hypersensitivity hepatitis.
1974 Oct 21
The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties.
1975
Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines.
1978 Dec
Neuroleptic-induced acute dyskinesias in rhesus monkeys.
1981
Differential diagnosis of cimetidine-induced delirium.
1981 Mar
Opposite effects of chlordiazepoxide and serotonin receptor antagonists on morphine-induced locomotor stimulation in mice.
1982
Effect of benzodiazepines on the central action of narcotic analgesics.
1982
Acute lithium-induced tremor.
1983 Jul
Incidence and potentiation of external and internal fetal anomalies resulting from chlordiazepoxide and amitriptyline alone and in combination.
1984 Aug
Chlordiazepoxide enhances the anxiogenic action of CGS 8216 in the social interaction test: evidence for benzodiazepine withdrawal?
1985 Jul
Antagonism of drug-induced yawning and penile erections in rats.
1986 Mar 18
Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?
1987
The effects of lindane, DDT, and chlordecone on avoidance responding and seizure activity.
1987 Mar 30
Inhibition of the binding and the behavioral effects of thyrotropin-releasing hormone (TRH) by the triazolobenzodiazepines.
1988 May
Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor.
1988 May
Anticonvulsive and convulsive effects of lidocaine: comparison with those of phenytoin, and implications for mechanism of action concepts.
1988 Sep
Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells.
1989
Evidence that the increased anxiety detected in the elevated plus-maze during chlordiazepoxide withdrawal is not due to enhanced noradrenergic activity.
1989 Dec
Caffeine-induced anxiogenesis: the role of adenosine, benzodiazepine and noradrenergic receptors.
1989 Jan
Chlordiazepoxide metabolite accumulation in liver disease.
1989 Jan-Feb
Inhibition by antimanic drugs of hyperactivity induced by methamphetamine-chlordiazepoxide mixture in mice.
1990 Apr
Expression cloning of a cDNA encoding the mouse pituitary thyrotropin-releasing hormone receptor.
1990 Dec
Effects of DM-9384, a pyrrolidone derivative, on alcohol- and chlordiazepoxide-induced amnesia in mice.
1990 Jun
Absence of tumor initiating effect in the liver of rats treated with chlordiazepoxide plus sodium nitrite.
1990 Sep-Oct
Prenatal oxazepam enhances mouse maternal aggression in the offspring, without modifying acute chlordiazepoxide effects.
1991 Jan-Feb
Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial.
1991 Mar
Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents.
1993 Jun 24
The attenuation of suppression of motility by triazolam in the conditioned fear stress task is exacerbated by ethanol in mice.
1995
Microinfusion of pituitary adenylate cyclase-activating polypeptide into the central nucleus of amygdala of the rat produces a shift from an active to passive mode of coping in the shock-probe fear/defensive burying test.
2007
Emerging synergisms between drugs and physiologically-patterned weak magnetic fields: implications for neuropharmacology and the human population in the twenty-first century.
2007 Dec
Involvement of noradrenergic and corticoid receptors in the consolidation of the lasting anxiogenic effects of predator stress.
2007 May 16
Pharmacological modulation of stress reactivity dissociates general learning ability from the propensity for exploration.
2007 Oct
Palmar-plantar erythrodysesthesia caused by mercaptopurine and mesalamine.
2008 Aug
Overlapping and distinct brain regions associated with the anxiolytic effects of chlordiazepoxide and chronic fluoxetine.
2008 Aug
Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs.
2009 Jan 14
Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
2009 Mar 17
A transposon in Comt generates mRNA variants and causes widespread expression and behavioral differences among mice.
2010 Aug 17
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010 Dec
Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults.
2010 Dec 2
Hydroxyzine for generalised anxiety disorder.
2010 Dec 8
Relations between open-field, elevated plus-maze, and emergence tests in C57BL/6J and BALB/c mice injected with GABA- and 5HT-anxiolytic agents.
2010 Jun
A dopaminergic gene cluster in the prefrontal cortex predicts performance indicative of general intelligence in genetically heterogeneous mice.
2010 Nov 17
Patents

Sample Use Guides

Relief of Mild and Moderate Anxiety Disorders and Symptoms of Anxiety: 5 mg or 10 mg, 3 or 4 times daily Relief of Severe Anxiety Disorders and Symptoms of Anxiety: 20 mg or 25 mg, 3 or 4 times daily Geriatric Patients, or in the presence of debilitating disease: 5 mg, 2 to 4 times daily
Route of Administration: Oral
In Vitro Use Guide
Eight concentrations of Chlordiazepoxide were added to tubes containing rat brain membranes and [3H]diazepam at a final concentration of 4 mkM. After incubation at 30 C for 10 min, followed by 4 C for 20 min, reactions were terminated by vacuum filtration through Whatman GF/C glass-fiber filters. Nonspecific binding was determined in the presence of 4 mkM unlabeled diazepam. The IC50 of a compound was that concentration resulting in 50% inhibition of [3H]diazepam binding to the membrane fraction.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:53:25 UTC 2021
Edited
by admin
on Fri Jun 25 20:53:25 UTC 2021
Record UNII
MFM6K1XWDK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORDIAZEPOXIDE HYDROCHLORIDE
EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [MI]
Common Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
LYGEN
Brand Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [WHO-DD]
Common Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [MART.]
Common Name English
CHLORDIAZEPOXIDE HCL
Common Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
7-CHLORO-2-(METHYLAMINO)-5-PHENYL-3H-1,4-BENZODIAZEPINE 4-OXIDE MONOHYDROCHLORIDE
Systematic Name English
3H-1,4-BENZODIAZEPIN-2-AMINE, 7-CHLORO-N-METHYL-5-PHENYL-, 4-OXIDE, MONOHYDROCHLORIDE
Common Name English
LIBRIUM
Brand Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [JAN]
Common Name English
RO 5-0690
Code English
RO-5-0690
Code English
CHLORDIAZEPOXIDE HYDROCHLORIDE [VANDF]
Common Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE CIV [USP-RS]
Common Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [USAN]
Common Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE [USP-RS]
Common Name English
A-POXIDE
Brand Name English
CHLORDIAZACHEL
Brand Name English
CHLORDIAZEPOXIDE HYDROCHLORIDE CIV
USP-RS  
Common Name English
NSC-115748
Code English
Classification Tree Code System Code
NCI_THESAURUS C1012
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
EPA PESTICIDE CODE 600092
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
Code System Code Type Description
USP_CATALOG
1110009
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY USP-RS
FDA UNII
MFM6K1XWDK
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY
ECHA (EC/EINECS)
207-117-8
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY
DRUG BANK
DBSALT000632
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY
EVMPD
SUB01213MIG
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY
MERCK INDEX
M3355
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL451
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY
NCI_THESAURUS
C47973
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY
CAS
438-41-5
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY
RXCUI
203173
Created by admin on Fri Jun 25 20:53:25 UTC 2021 , Edited by admin on Fri Jun 25 20:53:25 UTC 2021
PRIMARY RxNorm
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY